Abstract Library

#2903 Bone Metastases (BM) in Neuroendocrine Tumors (NET): Imaging Characteristics and Clinical Implications. A Single-Institution Experience

Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Smiroldo V

Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, Zerbi A,

Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan,

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,

#1912 Skeletal-Related Events (SREs) and Use of Antiresorptive Therapy (ART) in Patients with Bone Metastases of Neuroendocrine Neoplasms

Introduction: Antiresorptive therapy (ART) with bisphosphonates or denosumab is effective in preventing skeletal-related events (SREs) in patients with bone metastases (BM). In neuroendocrine neoplasms (NEN), BM are a negative prognostic factor, however tend to be asymptomatic and SREs are considered rare. The role of ART in preventing SREs in NEN has not been investigated so far.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Apostolidis L, Jäger D, Winkler E,

Keywords: NEN, bone metastases, antiresorptive treatment, bisphosphonates, denosumab,